Subtle Medical, an AI-powered medical imaging company, received Phase II funding from a NIH SBIR grant to expand its SubtleSYNTH technology into brain imaging. The company also received FDA approval for generating SynthSTIR images in spinal imaging, offering zero acquisition time while maintaining clinical quality. SubtleSYNTH aims to enhance the efficiency and accuracy of MRI procedures, addressing backlogs and scheduling challenges. This funding allows Subtle Medical to push the boundaries of medical imaging technology. The company raised close to $10 million in a recent funding round to accelerate sales initiatives and launch new AI-driven products. The company’s SubtleMR software allows for accelerated image acquisition in MRI procedures.
Source link
Subtle Medical receives Phase II funding approval to boost imaging technology
